TY  - JOUR
AU  - Diez-Echave, Patricia
AU  - Vezza, Teresa
AU  - Algieri, Francesca
AU  - Ruiz-Malagon, Antonio Jesús
AU  - Hidalgo-Garcia, Laura
AU  - Garcia, Federico
AU  - Moron, Rocio
AU  - Sanchez, Manuel
AU  - Toral, Marta
AU  - Romero, Miguel
AU  - Duarte, Juan
AU  - Garrido-Mesa, Jose
AU  - Rodriguez-Cabezas, Maria Elena
AU  - Rodriguez-Nogales, Alba
AU  - Galvez, Julio
PY  - 2022
DO  - 10.1016/j.biopha.2022.113445
UR  - http://hdl.handle.net/10668/22045
T2  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
AB  - Melatonin has shown beneficial effects on obesity, both in humans and experimental models, via regulating the altered circadian rhythm and thus ameliorating the gut dysbiosis associated with this metabolic condition. However, its clinical use is...
LA  - en
PB  - Elsevier Masson
KW  - Agomelatine
KW  - Melatonin
KW  - Metabolism
KW  - Metformin
KW  - Microbiome
KW  - Obesity
KW  - Acetamides
KW  - Animals
KW  - Diet, High-Fat
KW  - Dysbiosis
KW  - Gastrointestinal Microbiome
KW  - Humans
KW  - Male
KW  - Melatonin
KW  - Mice
KW  - Mice, Inbred C57BL
KW  - Naphthalenes
KW  - Obesity
TI  - The melatonergic agonist agomelatine ameliorates high fat diet-induced obesity in mice through the modulation of the gut microbiome.
TY  - research article
VL  - 153
ER  -